James Bryan Diaz, MD
Internal Medicine · San Juan, PRNPI 1932413499
Payments from drug & device makers
Across 131 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$649
- Johnson & Johnson$360
- AbbVie$294
- PBG Puerto Rico LLC$259
- E.r. Squibb & Sons, L.L.C.$246
- Boehringer Ingelheim$200
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,101100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 29 | $649 |
| Johnson & Johnson | 14 | $360 |
| AbbVie | 12 | $294 |
| PBG Puerto Rico LLC | 11 | $259 |
| E.r. Squibb & Sons, L.L.C. | 10 | $246 |
| Boehringer Ingelheim | 5 | $200 |
| Sanofi-aventis U.S. LLC | 7 | $144 |
| Eli Lilly Export S.A. Puerto Rico Branch | 6 | $133 |
| GSK | 4 | $97 |
| Bayer | 4 | $97 |
| Eisai Inc. | 4 | $84 |
| Exelixis Inc. | 3 | $67 |
| Morphosys, US Inc. | 3 | $65 |
| Novartis | 3 | $64 |
| Sanofi | 2 | $47 |
| Puma Biotechnology, Inc. | 2 | $44 |
| Merck | 2 | $43 |
| Amgen | 2 | $41 |
| Incyte Corporation | 2 | $37 |
| Exact Sciences | 1 | $25 |
| Bayer Puerto Rico Inc. | 1 | $25 |
| Pfizer | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Bristol Myers Squibb | 1 | $18 |
| Partner Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$100
How this compares
$3,101 in reported general payments places this provider in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $77,804 |
| FarxigaDapagliflozin Propanediol | 83 | $55,583 |
| JardianceEmpagliflozin | 45 | $42,169 |
| XareltoRivaroxaban | 60 | $36,670 |
| JanuviaSitagliptin Phosphate | 37 | $35,516 |
| OzempicSemaglutide | 29 | $32,165 |
| SynthroidLevothyroxine Sodium | 341 | $29,047 |
| EntrestoSacubitril/Valsartan | 31 | $20,386 |
| MounjaroTirzepatide | 19 | $20,377 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $19,292 |
| TradjentaLinagliptin | 17 | $14,127 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $12,386 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $9,223 |
| Candesartan Cilexetil | 65 | $8,891 |
| BrilintaTicagrelor | 12 | $8,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $23 | $77,804113 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $649 | $66,841106 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $200 | $65,51973 claims |
| MerckJanuvia, Janumet Xr | $43 | $54,80953 claims |
| Johnson & JohnsonXarelto | $360 | $36,67060 claims |
| AbbVieSynthroid | $294 | $29,047341 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $97 | $25,16046 claims |
| NovartisEntresto | $64 | $20,38631 claims |
| Sanofi-aventis U.S. LLCLantus | $144 | $5,30366 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in San Juan
- Grisell Ortiz LasantaSan Juan$5.9M
- Ricardo FernandezSan Juan$480K
- Pedro del Valle de TomasSan Juan$114K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Roberto Calderon SantiagoSan Juan$20K
- Natalia Almodovar ArbeloSan Juan$9K
- Jeremy FelicianoSan Juan$8K
- Porfirio Diaz-RodriguezSan Juan$8K
- Rafael Figueroa NavarroSan Juan$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.